Focus Rheums| ACR Convergence 2024 Previews

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Interferon Score Predicts AI-CTDs

  |  Issue: November 2018  |  

Susan Bernstein is a freelance journalist based in Atlanta.

References

  1. 1. Md Yusof MY, Psarras A, El-Sherbiny YM, et al. Prediction of autoimmune connective tissue disease in an at-risk cohort: Prognostic value of a novel two-score system for interferon status. Ann Rheum Dis. 2018 Oct;77(10):1432–1439.
  2. 2. El-Sherbiny YM, Psarras A, Md Yusof MY, et al. A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features. Sci Rep. 2018;8(1):5793.
  3. 3. Zayat AS, Md Yusof MY, Wakefield RJ, et al. The role of ultrasound in assessing musculoskeletal symptoms of systemic lupus erythematosus: A systematic disease review. Rheumatology (Oxford). 2016 Mar;55(3):485–494.
  4. 4. Zahn S, Rehkamper C, Kummerer BM, et al. Evidence for a pathophysiological role of keratinocyte-derived type-III interferon (IFNγ) in cutaneous lupus erythematosus. J Invest Dermatol. 2011 Jan;131(1):133–140.

Related Articles

    When Interstitial Lung Disease and Connective Tissue Disorder Intersect in Rheumatology Patients

    SAN FRANCISCO—Interstitial lung disease (ILD) represents a heterogeneous group of disorders characterized by inflammation or fibrosis of the lungs. The disorders are also associated with a spectrum of connective tissue diseases (CTDs). ILD is a common manifestation of CTDs, such as scleroderma, poly-/dermatomyositis and rheumatoid arthritis—and is a leading cause of morbidity and mortality in…

    Summit on Connective Tissue Disease-Associated ILD Fosters Interdisciplinary Dialogue

    During an international summit, physicians and researchers discussed the key clinical and research aspects of the complex intersection between connective tissue diseases and interstitial lung disease (ILD), proposing initiatives to raise awareness and conduct research to better serve patients with autoimmune forms of ILD…